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Background: Epithelial ovarian carcinoma is a deadly disease characterized by overt peritoneal metastasis.
Individual cells and multicellular aggregates, or spheroids, seed these metastases, both commonly found in ascites.
Mechanisms that foster spheroid attachment to the peritoneal tissues preceding formation of secondary lesions are
largely unknown.
Methods: Cell culture models of SKOV-3, OVCAR3, OVCAR4, Caov-3, IGROV-1, and A2780 were used. In this report
the role of versican was examined in adhesion of EOC spheroids and cells to peritoneal mesothelial cell monolayers
in vitro as well as in formation of peritoneal tumors using an in vivo xenograft mouse model.
Results: The data demonstrate that versican is instrumental in facilitating cell and spheroid adhesion to the
mesothelial cell monolayers, as its reduction with specific shRNAs led to decreased adhesion. Furthermore,
spheroids with reduced expression of versican failed to disaggregate to complete monolayers when seeded atop
monolayers of peritoneal mesothelial cells. Failure of spheroids lacking versican to disaggregate as efficiently as
controls could be attributed to a reduced cell migration that was observed in the absence of versican expression.
Importantly, both spheroids and cells with reduced expression of versican demonstrated significantly impaired
ability to generate peritoneal tumors when injected intraperitoneally into athymic nude mice.
Conclusions: Taken together these data suggest that versican regulates the development of peritoneal metastasis
originating from cells and spheroids.
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Epithelial ovarian carcinoma (EOC) is a leading cause of
death from gynecologic malignancies and the fifth leading
cause of death in women [1]. Nearly 90% of all ovarian
cancer cases are epithelial in origin and the majority of
those belong to a serous histotype. Metastatic disease is
highly lethal, and less than 20% of the affected patients
survive over a 5 year interval [2,3]. Metastatic progression
of EOC is very unique, as metastases that cause death
spread locoregionally, in the peritoneal cavity [2]. Malig-
nant cells are shed off of the primary tumor and are car-
ried by the intraperitoneal ascitic fluid, which is followed
by implantation at the organs and tissues of the peritoneal* Correspondence: mvb@uic.edu
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article, unless otherwise stated.cavity, anchorage in submesothelial ECM and establish-
ment of metastases [4,5]. Shed EOC cells may exist as sin-
gle cells and multicellular aggregates, or spheroids, and
both are capable of attaching to the mesothelial layer and
transmigrating through outlining peritoneal tissues and
organs [6,7].
Successful colonization of the abdomen by EOC cells
and spheroids to a large extent depends on their ability to
attach to mesothelial surfaces of the peritoneal organs and
tissues. EOC cell adhesion to omental “milky spots” com-
posed of various cell types including mesothelial has also
been reported [8]. Mesothelial cells are specialized cells
that outline the entire surface of the peritoneal cavity.
These cells, among other functions, provide a protective
barrier against invading pathogens and secrete surfactant
molecules to provide a non-adhesive surface. Multiple in-
teractions between EOC cells and mesothelial cells havetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cluding CD44-hyaluronan, α5β1-integrin-fibronectin, L1-
neuropilin-1, CA125-mesothelin, and CX3CL1-CX3CR1
[9-16]. Information regarding the mechanisms of EOC
spheroid adhesion to the mesothelium is scarce and limited
to a single report suggesting the role of β1-integrins in this
process [4]. Inhibition of spheroid adhesion could be essen-
tial in preventing secondary lesions, as these multicellular
aggregates can efficiently escape chemotherapy and radi-
ation, as shown using in vitro models, which might contrib-
ute to recurrence of EOC in treated patients [4,17-19].
Versican (VCAN) is a secreted proteoglycan protein
with multiple functions that can promote tumor metasta-
sis [20,21]. Versican can be expressed in at least 5 different
splice variants that were reported to affect cell-cell and
cell-matrix adhesion [22-24], migration [25], proliferation,
apoptosis [26], and a mesenchymal-epithelial transition
[27]. Versican contains several domains [28] that define its
binding partners: hyaluronan, integrin, CD44, selectins,
EGFR, chemokines, and many others (reviewed in [21]).
The exact composition of versican domains varies in each
isoform, however the N-terminal hyaluronan-binding and
the C-terminal domains are present in all isoforms. Spatial
and temporal regulation of versican expression is regu-
lated by very diverse pathways, such as the canonical
Wnt/β-catenin signaling [29,30], androgen receptor signal-
ing [31], transcription factor AP-1 [30], microRNA miR-
143 [32], and others (reviewed in [33]). Importantly, 50%
of tested primary EOC (n = 299) expressed versican [34].
Moreover, overexpression of versican in malignant ovarian
stroma is associated with increased invasive potential [35].
Versican could stabilize pericellular matrix and enable
stronger adhesion of EOC cells to the mesothelial cells via
a CD44-dependent mechanism [15,36]. Furthermore, our
previous data demonstrated upregulation of versican in
spheroids [37], prompting further studies into the role of
this ECM-associated protein in the biology of EOC spher-
oids and EOC. In this report, we have investigated the role
of versican in individual cell and spheroid adhesion, mi-




Matrigel and rat tail collagen type I was obtained from BD
Biosciences (Bedford, MA). Human versican shRNA
constructs in retroviral GFP vector were obtained from
Origene (Rockville, MD). Human versican (pool of 3 pro-
prietary 19 – 25 nt sequences) and control siRNAs were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
DharmaFECT1 was obtained from Dharmacon (Lafayette,
CO). Mouse anti-human versican antibody clone 12C5 and
mouse anti-human-β-tubulin were obtained from Iowa De-
velopmental Studies Hybridoma Bank (Iowa City, Iowa).Cell lines
Human ovarian carcinoma cell lines of serous histotype
originating from malignant cells in ascites, OVCAR4,
SKOV-3 and A2780, were obtained from the NCI Tumor
Cell Repository (Detrick, MD). These cell lines were cul-
tured as suggested by the manufacturer for no longer than
twenty consecutive passages. The human ovarian carcin-
oma cell line of serous histotype originating from malig-
nant cells in ascites, Caov-3, was obtained from Dr. M.S.
Stack (University of Notre Dame, ID) and propagated in
minimal essential media supplemented with 10% fetal bo-
vine serum (FBS) for no longer than fifteen consecutive
passages. OVCAR3 was obtained from ATCC and cul-
tured as recommended. The human ovarian carcinoma
cell line of serous histotype originating from a primary
tumor, IGROV-1, was obtained from the NCI Tumor Cell
Repository (Detrick, MD) and cultured as suggested by
the manufacturer for no longer then twenty consecutive
passages. The human immortalized peritoneal mesothelial
cell line LP-3 was obtained from the Coriell Aging Cell
Repository (Camden, NJ) and cultured as indicated by the
manufacturer for 5–8 passages. All cell lines were rou-
tinely assessed for cellular morphology and average doub-
ling time. All cell lines were propagated from stocks
originally obtained from cell banks and individual investi-
gators and have been stored in aliquots for future use.
Each aliquot was further propagated for no longer than 20
consecutive passages or 4 months, whichever came first.
Mice
Athymic nude – FOXN1NU mice were obtained from
Harlan Laboratories (Madison, WI) and from Charles
River Laboratories (Chicago, IL). All experimental pro-
cedures were performed according to the Institutional Ani-
mal Care and Use Committee protocol (#10-060) approved
by the Animal Care Committee of UIC. Animals were fed
ad libitum and maintained in Association for Assessment
and Accreditation of Laboratory Animal Care International
approved facilities on a 12 h light 12 h dark cycle.
Transient transfections
EOC cells were cultured to 80% confluence and trans-
fected with siRNAs using DharmaFECT1 according to
the manufacturer’s instructions.
Creating stable clones with reduced VCAN expression
SKOV-3 were transfected with VCAN shRNAs following
manufacturer’s suggestions. To create VCAN shRNA-
silenced sub cell lines we have used the following four dif-
ferent shRNA sequences designed against multiple splice
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their resistance to puromycin and expression of GFP. Re-
sidual expression of 5 known isoforms of VCAN has been
determined using qPCR resulting in selection of several
clones for further experiments.
Quantitative real-time PCR
Real-time PCR was performed using MyiQ (Bio-Rad) ac-
cording to the manufacturer’s instructions. Primers for de-
tection of V0, V1, V2, and V3 isoforms of VCAN and a
housekeeping gene control eukaryotic translation elong-
ation factor 1 alpha 1 (EEF1A1) have been synthesized
using previously reported sequences [38]. The primers for
mRNA detection of V4 isoform of VCAN were con-
structed according to requirements for oligonucleotide
primers for quantitative real-time PCR using the Primer3
software. Primer specificity was determined using serial di-
lutions of the template and by examination of the product
melting curves. SYBR Green was used for quantitative
PCR as a double-stranded DNA-specific fluorophore. PCR
was conducted by initial denaturation for 10 min at 95°C
followed by 40 cycles of 94°C for 15 sec and 60°C for
30 sec using the iTaq SYBR Green Supermix (BIO-RAD).
To determine the specificity of the PCR primers, the melt-
ing curves were collected by denaturing the products at
95°C, then cooling to 65°C, and then slowly melting at
0.5°/sec up to 95°C.
Spheroid formation
Spheroids were generated using an agarose overlay
method described previously [39]. Briefly, non-adhesive
agarose plates were prepared by solidifying agarose solu-
tion (0.5% in complete culture media) in cell culture
plates. EOC cells were released from the monolayers with
0.05% trypsin/EDTA solution, suspended in media con-
taining 2% fetal bovine serum at the concentration of
125,000 cells/ml. 2 ml of this solution was added atop of
the solidified agarose and incubated for 48 h at 37°C and
5% CO2. Spheroids formed in the suspension and were vi-
sualized using bright field microscopy and their diameters
measured using AxioVision software (Zeiss). Spheroids
were collected from the media with gentle centrifugation
for 1 min at 30 × g.
Cell-cell adhesion and spheroid disaggregation
A human-derived peritoneal mesothelial cell-line LP-3
was cultured in 96-well plates to near confluence. SKOV-3
cells were cultured in monolayers and labeled with fluor-
escent DiI (Invitrogen) according to the manufacturer’s in-
structions prior to the adhesion assays. SKOV-3 were
subsequently released from monolayers with 0.05% tryp-
sin/EDTA solution and resuspended in serum-free cell
culture media. To study adhesion and disaggregation of
spheroids, SKOV-3 in monolayers were labeled with DiIand subjected to the spheroid formation assay followed by
plating atop of the confluent monolayer of LP-3 (in tripli-
cate per condition) in serum-free media. When needed,
SKOV-3 cells were transiently transfected with either con-
trol or VCAN-specific siRNAs and used in adhesion as-
says between 48 and 72 h from the start of transfection.
Several clones of SKOV-3 stably transfected with VCAN
shRNAs were also used along with the controls stably
transfected with scrambled shRNA. Subsequently, the
monolayers were washed two times with PBS and fixed in
a methanol-containing cell fixative. Adherent cells show-
ing round cell morphology were visualized by red fluores-
cent signals using a Zeiss fluorescent microscope. The
adherent DiI-labeled cells were counted, averaged, and
characterized as a percentage from the total. To analyze
the role of VCAN in spheroid disaggregation, adherent
spheroids were allowed to disaggregate for 24 h followed
by outlining the outer perimeter and quantifying the total
area taken by the disaggregated spheroid using AxioVision
software (Zeiss). Area fold change was calculated by divid-
ing the total area of disaggregated spheroid by that of the
spheroid at time zero.
Cell-ECM adhesion and spheroid disaggregation
Tissue culture-treated 48-well plates were pre-coated with
10 μg/ml human collagen type I and Matrigel (diluted
1:100), or PBS (designated “culture plate”) for 1 h at 37°C.
The plates were subsequently rinsed with PBS and air
dried. Next, 10 000 SKOV-3 cells were seeded (in triplicate
for each condition) in serum-free media in coated wells
and allowed to adhere for 5 h at 37°C and 5% CO2. This
seeding was followed by two washes with PBS, fixation in
a methanol-containing cell fixative, and staining. Cells
were counted, averaged, and plotted. Spheroids were
seeded in serum-free media and allowed to disaggregate
for 24 h followed by data analysis including calculation of
the area fold change as described above for spheroid disag-
gregation on LP-3.
Wound healing assay
To study cell migration using wound healing assays, cells
were cultured to complete monolayers in complete media
containing 10% FBS followed by 24 h incubation in a
media containing no FBS or other growth factors. Wounds
were introduced with a plastic pipette tip. Cells cultured
in serum-free media were monitored for up to 10 h and
photographed using Zeiss AxioVision software. Wound
healing was calculated based on the widths of the initial
wounds (0 time point) and those at 5 and 10 h and derived
as a percentage from the initial. Measurements of the gaps
were taken in 10 random places along the wounds, aver-
aged, and percentage of wound healing was calculated
based on the lengths of gaps at the initial wounding and at
5 and 10 h, respectively.
Desjardins et al. Journal of Ovarian Research 2014, 7:70 Page 4 of 12
http://www.ovarianresearch.com/content/7/1/70Transwell cell migration
Inserts with 0.8-micron porous membranes were bottom-
coated with 1:100 diluted Matrigel for 1 h at 37°C, rinsed,
and air-dried. SKOV-3 and IGROV-1 cells (5,000/trans-
well) in a final volume of 300 μl were seeded in the inserts,
which were then placed into 24-well plates filled with
serum-free minimal essential media. The cells were
allowed to migrate for 5 h at 37°C and 5% CO2. Migration
was stopped by removing the non-migrated cells from the
inside of the inserts. Cells that had migrated through the
membranes were fixed, stained, and counted.
Flow cytometry
The monolayer cells (1×106 per tube) were harvested with
trypsin/EDTA and spheroids were harvested with centrifu-
gation and brought to the individual cell state with tryp-
sin/EDTA. Further cells were resuspended in 100 μl of ice
cold PBS supplemented with 10% fetal calf serum and 1%
sodium azide, fixed in a 1% paraformaldehyde solution in
PBS for 15 min on ice, and permeabilized using methanol
for 1 h at −20°C. 2 mg of mouse anti-human versican anti-
body (clone 12C5, Iowa Developmental Studies Hybrid-
oma Bank) was added to the cells. For negative controls,
the cells were incubated with either 2 μg of anti-mouse
IgG antibody or no primary antibody. Cells were incu-
bated for 1 h on ice in the dark with agitation following
washing and resuspension in 400 μl ice cold PBS. 2 μg of
goat anti-mouse FITC-conjugated IgG (Millipore) was
added to the cells and incubated for 1 h on ice in the dark
with agitation. The cells were washed and resuspended in
400 μl of ice cold PBS supplemented with 2% BSA and 1%
sodium azide. Labeled cells were analyzed using an Accuri
C6 flow cytometer on the same day.
Immunofluorescence staining
The cells were cultured on glass coverslips to nearly full
confluence, fixed, and blocked in goat serum. Mouse anti-
human-versican (clone 12C5) antibodies were used at a
1:100 dilution and incubated with cells for 1 h at 22°C. Sec-
ondary anti-mouse Alexa433- or anti-mouse Alexa594-
conjugated antibodies were used at 1:500 and incubated
with cells for 1 h at RT in the dark. 4',6-Diamidino-2-phe-
nylindole (DAPI) was added to the secondary antibody so-
lution to a final concentration of 10 μg/ml 10 min prior to
the end of the incubation period. The cells were washed, air
dried, and mounted on glass slides using ProlongGold
(Invitrogen, Carlsbad, CA). Fluorescent imaging was
performed using a Zeiss AxioObserverD.1 fluorescence
microscope.
Western blot
Western blotting analysis was used to detect the expres-
sion of versican and β-tubulin in SKOV-3 cells and
spheroids. This procedure was performed as previouslydescribed [40-42]. Antibodies were used at the following di-
lutions: 1:100 mouse anti-human-versican (clone 12C5) in
3% BSA in a solution of 50 mM tris-buffered saline, pH 7.4,
150 mM NaCl, and 0.05% Tween-20 (TBST) (Sigma; St.
Louis, MO) and 1:200 mouse anti-human-β-tubulin in 3%
BSA in TBST. Immunoreactive bands were visualized with
an anti-(mouse-IgG)-peroxidase (Sigma, St. Louis, MO)
(1:1000 in 3% BSA in TBST), and enhanced chemilumines-
cence was read using Chemidoc (Bio-Rad) and Bio-Rad
Chemidoc ImageReader software.
In vivo tumor formation
For generation of intraperitoneal tumors 3 × 106 cells/
mouse of parental SKOV-3 and SKOV-3 stably expressing
VCAN shRNA (2 clones) were used to generate spheroids.
Spheroids were injected intraperitoneally (i.p.) into athymic
nude mice (n = 6) and animals were monitored three times
weekly for tumor formation, ascites development, and sur-
vival up to 38 days. To generate intraperitoneal tumors
from individual cells, 3 × 106 SKOV-3/mouse were i.p.
injected into athymic nude mice (n = 6) and animals were
monitored three times weekly for tumor formation, ascites
development, and survival for up to 10 weeks. At the end
of the experiments animals were sacrificed, dissected, asci-
tes were aspirated, and the abdominal region was examined
for tumors. Data analysis was performed as “yes” in case
when tumor were visible and “no” when no nodules were
seen regardless of the size found at a specific abdominal
organ or tissue and plotted as a bar graph depicting the
number of animals bearing metastasis at the indicated tis-
sues and organs. Tumors were collected and paraffin-
preserved as described earlier [43].
Statistical analysis of the results of in vivo experiments
The data were treated as coded values for the presence or
absence of tumor and compared between the control
(SKOV-3) and the SKOV-3 versican shRNA clones 5 and
6 (spheroids). A Chi-square analysis was performed and
identified that VCANsh clone6 and VCANsh clone5 were
significantly different than the control for all sites in the
spheroid groups and VCANsh clone6 was significantly dif-
ferent than the control for all sites in the single cell group
(Pearson Chi-square = 13.846, p = 0.001, with a Fisher's
exact correction at 0.002).
Results
Expression of versican is upregulated in EOC spheroids
All versican isoforms detected in SKOV-3, IGROV-1,
Caov-3, OVCAR3, and A2780 were expressed at different
levels (Figure 1A). V2 was expressed only by OVCAR4,
while V4 was not detected in any of the EOC cell lines (not
shown). V0, V1, and V3 isoforms of versican were upregu-
lated in spheroids of SKOV-3, IGROV-1, and OVCAR3












































































   
   
   
   








































Figure 1 Expression of VCAN in EOC monolayer cells and spheroids. (A) Expression of VCAN isoforms V0, V1, and V3 in the indicated EOC
cell lines has been tested using QPCR. EEF1A1 served as a housekeeping gene control. (B) Expression of VCAN isoforms V0, V1, and V3 was
detected in the indicated EOC cell lines cultured in monolayers or as spheroids. Ct values were normalized against those corresponding to the
housekeeping gene control EEF1A1. Presented is an average of at least three independent experiments; bars designate the standard deviation.
(C) Expression of versican V3 in individual cells released from monolayers (termed “single”) and spheroids of SKOV-3 was detected using Western
blot. Expression of versican V3 was quantified using optical densitometry, normalized to the expression of a housekeeping gene β-tubulin, and
statistically analysed using t-test between spheroid and monolayer groups. (D) Expression of versican in monolayers and spheroids of SKOV-3,
OVCAR3, and OVCAR4 was assessed using immunofluorescence staining. Bar, 50 micron. Intensity of the versican staining in disaggregated
spheroids and monolayers was measured using AxioVert software (Zeiss). Areas occupied by disaggregated spheroids were outlined to measure
total intensity of the fluorescence signal, averaged, and plotted in the histogram. Student’s t-test was used to analyze differences in versican
fluorescence staining in spheroids and monolayers.
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hancement of cellular functions facilitated by V0, V1, and
V3 in EOC spheroids. Furthermore, a robust versican pro-
tein upregulation in spheroids of SKOV-3, OVCAR3, and
OVCAR4 was also detected using Western blot and im-
munofluorescence staining (Figure 1C,D). A recent study
compared genomic profiles of ovarian carcinoma and a lim-
ited number of human-derived cell lines with the purpose
of identifying cell lines with highest genomic similarity to
human tumors [44]. Based on those results, OVCAR3 and
OVCAR4 were likely derived from high-grade serousovarian cancer. SKOV3 from ATCC is a model of ovarian
cancer, but not high grade, because it is wild-type for p53
[44]. The SKOV3 cell line used in the current study was ob-
tained from the NCI Cell Repository and was different than
the cell line studied in [44]. For example, the currently used
SKOV3 was null for p53 (Additional file 1: Figure S1A),
thus providing further justification for the use of this cell
line as a good model as most of EOC contain inactivating
mutations in p53 [45]. These cell models were chosen for
further examination of versican in EOC spheroids because
they displayed increase of versican expression in spheroids
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do not come apart upon gentle pipetting. SKOV3 was
chosen for functional studies of versican because it repli-
cates well the peritoneal spread of ovarian carcinoma when
injected intraperitoneally into abdomens of mice [43].
Reduction of versican expression affects EOC spheroid
and cell adhesion to peritoneal mesothelial cell
monolayer and ECM
Because versican was upregulated in spheroids (Figure 1A
and [37]), its role in EOC spheroid adhesion to mesothelial
cell monolayers was monitored. To address this question
versican was transiently and stably knocked-down in
SKOV-3 or IGROV-1 cells using versican-specific siRNAs
and shRNA constructs, respectively. Flow cytometry dem-
onstrated downregulation of versican in VCAN siRNA-
transfected cells compared to the controls (Additional file
1: Figure S1B). Residual expression of all isoforms of versi-
can in transiently transfected cells and stably transfected
clones was below the detection limit of quantitative RT-
PCR (Additional file 1: Figure S1C). Immunofluorescent
staining revealed reduced versican expression in VCAN
siRNAs transfected cells and clones 5 and 6 generated by
stable transfection with shRNAs that was quantitatively
analysed using ImageJ software (Additional file 2: Figure
S2 and Additional file 3: Figure S3). In order to study ad-
hesion, changes at the terminal time point, 5 h in case of
SKOV-3 was chosen, when the majority of cells have ad-
hered, as opposed to studying the kinetics of attachment
to different substrates. Both versican-specific siRNA and
shRNA were able to reduce adhesion of EOC spheroids to
the monolayers of peritoneal mesothelial cells LP-3 by
about 25% (Figure 2A). Adhesion of individual EOC cells
was also reduced upon siRNA- or shRNA-driven reduc-
tion of versican expression (Figure 2B). Furthermore, EOC
spheroid and cell adhesion to Matrigel and collagen type I
was reduced by about 20-25% as a result of downregula-
tion of versican (Figure 2). These data support a model
whereby increased versican expression in spheroids may
facilitate effective attachment to peritoneal mesothelial
monolayer and underlying ECM.
Versican regulates spheroid disaggregation on
mesothelial cell monolayers
A reduction of versican decreased the ability of EOC spher-
oids to disaggregate when seeded atop monolayers of peri-
toneal mesothelial cells LP-3 by approximately 35%
(Figure 3A,B). Further, EOC spheroids lacking versican dis-
aggregated on ECM and polystyrene supports yielding sig-
nificantly smaller total area compared to the controls
(Figure 3C). A reduction in total area during disaggregation
is an index of the cellular propensity to migrate. Versican
isoforms V0, V1, and V3 can contribute to cell migration
and metastasis [15,20,24,32,33,46]. In order to addresswhether versican was required for EOC cell migration, sev-
eral complimentary methods were used, such as a wound
healing assay and Transwell cell migration assay. A reduc-
tion of versican slowed the migratory ability of EOC cells
(Figure 4). SKOV-3 cells lacking versican migrated about
30% slower compared to the controls (Figure 4A,B), and
migration of IGROV-1 in the absence of versican was re-
duced by approximately 50% (Figure 4C). We investigated
whether loss of versican regulates changes in talin expres-
sion, as the latter has been demonstrated to play a role in
mesothelial monolayer clearance by spheroids [6], and we
found that talin RNA and protein remain unchanged (not
shown). Altogether these data suggest a possibility that
spheroid disaggregation on LP-3 is negatively affected by
loss of versican.
Loss of versican in EOC spheroids reduces formation of
peritoneal tumors
Our in vitro data indicated that the loss of versican hin-
dered the ability of EOC cells and spheroids to adhere to
peritoneal mesothelial cells, disaggregate, and migrate. All
of these affected cellular properties are important for a
tumor as well as a metastatic cell. To determine whether
the loss of versican observed in vitro played a role in any
of the steps of formation of peritoneal tumors, an in vivo
intraperitoneal xenograft model was utilized. Control and
versican-deficient spheroids were created using two differ-
ent clones stably transfected with versican shRNA, re-
spectively. The clones were intraperitoneally injected into
the abdomens of athymic nude mice and allowed to seed
and develop into peritoneal tumors. Loss of versican in
spheroids strongly impacted tumor formation, as both
SKOV-3 VCANsh clone5 and SKOV-3 VCANsh clone6
spheroids failed to generate tumors 5.5 weeks following i.
p. injection of tumor cells (Figure 5A,B). Passage through
the 25 g needle in the course of the intraperitoneal injec-
tion did not affect either the integrity of spheroids, or their
viability, or their ability to disaggregate (not shown). These
data indicate that versican could be one of key players in
the process of formation of secondary lesions by EOC
spheroids. To further examine the role of versican in peri-
toneal tumor formation by EOC, we conducted in vivo ex-
periments using the same cell lines, i.e. parental SKOV-3,
SKOV-3 VCANsh clone5, and SKOV-3 VCANsh clone6,
and i.p. injected them into athymic mice abdomens as in-
dividual cells in suspension (not spheroids). In this case,
the length of the experiment was increased to up to
10 weeks, as this longer endpoint resulted in a phenotype
consistent with the terminal point in metastasis formation
where animals become moribund and require sacrifice
[43]. Although SKOV-3 VCANsh clone5 and SKOV-3
VCANsh clone6 generated intraperitoneal tumors, the
overall tumor and ascites formation was robustly reduced
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Figure 2 Versican contributes to adhesion of EOC individual cells and spheroids to the peritoneal mesothelial cells LP-3, Matrigel, and
Collagen type I. Unmodified cell line SKOV-3 and its derivatives stably expressing scrambled shRNA and VCAN shRNA (2 clones were used: clone
2 and clone 5, as indicated), as well as SKOV-3 transiently transfected with either control or VCAN-specific siRNAs were converted into spheroids
and seeded (A), or seeded as individual cells (B). Presented is an average of at least three independent experiments; bars designate the standard
deviation. *p < 0.05, comparisons were made between experimental (VCANsi, VCANsh) and control (SKOV-3, Scr sh, Ctrl si) groups.
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and peritoneal wall, and had a small volume of ascites
(0.5 ml). In this group the other five animals did not have
any visible lesions, did not generate ascites, and were not
moribund at 10 weeks post tumor cell injection (Figure 5D).
In SKOV-3 VCANsh clone5 group three animals had peri-
toneal wall and colon metastasis, five had liver, stomach,
and mesentery metastasis, and all six had omental and
spleen metastasis (Figure 5C). However, in this group the
volume of ascites was significantly reduced as compared to
the parental SKOV-3 group (Figure 5D). The versican
groups overall had a lower tumor burden as all six of the
animals in the SKOV3 parental injected group developed
tumors at all location sites. Additionally, tumors generated
by SKOV-3 VCANsh clone5 were very small (up to 2–
10 mm3/site) as opposed to tumors in the parental group
(>1.5 cm3 in total); however, precise measurement of thevolumes and sizes was not possible due to overt tumor for-
mation in the parental group. The proliferation rate of
SKOV-3 VCANsh clone6 cells was significantly lower than
the controls, while SKOV-3 VCANsh clone5 cells prolifer-
ated similarly to the controls (Additional file 4: Figure S4).
These data may suggest that changes in proliferation could
have contributed to formation of tumors from individual
cells in SKOV-3 VCANsh clone6 group as compared to the
parental SKOV-3 and SKOV-3 VCANsh clone5.
Discussion
EOC, the deadliest gynecologic cancer, has many unique
features that set this malignancy apart from others and
make it difficult to treat clinically. The pattern of meta-
static spread involves peritoneal organs and occurs via dis-
semination of the malignant cells from the primary tumor,
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Figure 3 Versican contributes to EOC spheroid disaggregation. (A) Unmodified SKOV-3, SKOV-3 stably transfected with scrambled shRNA
and VCAN shRNA (2 different clones), and SKOV-3 transiently transfected with control or VCAN siRNA, as indicated, were labeled with fluorescent
DiI and used in spheroid formation assay. Measurements of the total area taken by spheroids were taken at 0 and 24 h time points and used for
calculation of the area fold change ratios. Presented is an average of at least 3 independent experiments; error bars represent standard deviation;
*p < 0.05, comparisons were made between experimental (VCANsi, VCANsh) and control (SKOV-3, Scr sh, Ctrl si) groups. (B) A typical image of
disaggregating SKOV-3 and SKOV-3 VCAN clone 5 spheroids taken at 0 and 24 h. Bar, 100 micron. (C) Unmodified SKOV-3, SKOV-3 stably transfected
with scrambled shRNA and VCAN shRNA (2 different clones), and SKOV-3 transiently transfected with control or VCAN siRNA, as indicated, were used in
spheroid formation assay. Presented is an average of at least 3 independent experiments; error bars represent standard deviation; *p < 0.05,
comparisons were made between experimental (VCANsi, VCANsh) and control (SKOV-3, Scr sh, Ctrl si) groups.
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http://www.ovarianresearch.com/content/7/1/70rare. Peritoneal spread of EOC metastasis is characterized
by numerous lesions seeded on various peritoneal tissues
and organs, leading to obstruction of bowel, malnutrition,
and death. Disseminated EOC cells can exist in the ascites
as individual cells and multicellular aggregates, which is
another unique feature of this malignancy. Although both
are capable of forming metastasis, it has been proposed
that spheroids may possess increased invasive ability [47].
Cells forming spheroids are less susceptible to the harmful
effects of chemotherapy and radiation in vitro, which may
allow them to escape treatment and proceed with periton-
eal metastases [17-19,39]. Follow-up chemotherapy in
EOC becomes significantly less efficient eventually leading
to development of incurable metastases. Thus, it is espe-
cially important to understand the biology of these poten-
tially more aggressive aggregates in order to prevent or
hamper formation of deadly peritoneal metastases. Ther-
apies preventing initial seeding from malignant spheroids
could lead to less metastatic lesions, better treatment out-
comes, and longer survival. New therapies could be usedafter surgical resection of primary EOC in early stage pa-
tients, as well as for reduction of further spread in patients
with advanced disease.
The data presented in this report indicate that a reduc-
tion of all forms of versican may abrogate formation of
peritoneal lesions seeded by EOC spheroids and it impedes
tumor formation by individual cells. Of note, tested cellular
properties that ensure success of metastasis, such as peri-
toneal adhesion, migration, and spheroid disaggregation,
were all reduced by only about 30% when versican expres-
sion was silenced according to the in vitro results. Tumor
lesions following intraperitoneal injection of spheroids that
were deficient for versican expression demonstrated a delay
in seeding such that no lesions were present at five and a
half weeks for both clones while tumors could be identified
although at a much lower level after ten weeks. These re-
sults might lead to a speculation that in some instances it
may be sufficient to abrogate multiple metastatic abilities,
but not necessarily to completely eliminate them in order
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Figure 4 Versican contributes to EOC cell migration. (A) Unmodified SKOV-3, SKOV-3 stably transfected with scrambled shRNA and VCAN
shRNA (3 different clones), and SKOV-3 transiently transfected with control or VCAN siRNA, as indicated, were cultured to complete monolayers
followed wounding with a pipette tip. Presented is an average of at least 3 independent experiments; error bars represent standard deviation;
*p < 0.05, comparisons were made between experimental (VCANsi, VCANsh) and control (SKOV-3, Scr sh, Ctrl si) groups. (B) Unmodified SKOV-3,
SKOV-3 stably transfected with scrambled shRNA and VCAN shRNA (3 different clones), and SKOV-3 transiently transfected with control or VCAN siRNA,
as indicated, were seeded in Transwell inserts and allowed to migrate for 5 h. Presented is an average of at least 3 independent experiments; error bars
represent standard deviation; *p < 0.05, comparisons were made between experimental (VCANsi, VCANsh) and control (SKOV-3, Scr sh, Ctrl si) groups.
(C) Unmodified IGROV-1, as well as IGROV-1 transiently transfected with control or VCAN siRNA, as indicated, seeded in Transwell inserts and allowed
to migrate for 5 h. Presented is an average of at least 3 independent experiments; error bars represent standard deviation; *p < 0.05, comparisons were
made between experimental (VCANsi,) and control (IGROV-1, Ctrl si) groups.
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http://www.ovarianresearch.com/content/7/1/70Alternatively, in the in vitro situation, spheroids may pre-
cipitate more easily due to gravitational forces, which would
allow for their tighter connection with the mesothelial layer.
In vivo, it is likely that completely different forces may con-
tribute to peritoneal adhesion of spheroids resulting in less
successful implantation. Other unknown factors could po-
tentially explain why no lesions after i.p. spheroid injection
were formed in our in vivo experiments at five and a half
weeks, even though they were able to form after 10 weeks
and in the in vitro studies they were reduced each only by a
third. Importantly, spheroids expressing versican (parental
SKOV-3 group) were able to form tumors, indicating that
the presence of versican is essential for seeding and devel-
opment of peritoneal lesions. Furthermore, our data suggest
that expression of endogenous versican could be important
for metastatic progression of EOC along with the stromal
versican previously reported by Ghosh [35]. Lastly, in the
conditions ensuring that animals injected with parentalSKOV-3 become moribund, individual cells lacking versi-
can expression were more successful in forming visible tu-
mors, perhaps, because they had more time to develop
visible tumors. These data suggest that versican is a key
protein that regulates peritoneal carcinomatosis by cells
and spheroids in a xenograft model of EOC.
It remains to be tested in more detail how abrogation of
versican in already existent metastasis might result in bet-
ter outcomes. It is important to mention that versican can
promote EOC cell proliferation [35]. However, our data do
not fully support that changes in proliferation contribute
to formation of tumors in our in vivo experiments, as cell
proliferation in one of the clones with reduced versican
expression was similar to the controls.
At present there are no specific small molecule drugs di-
rected at reduction of versican expression. Nevertheless,
other approaches that target the expression and function of
versican could be feasible in the future. Our experiments




















































Figure 5 Versican regulates formation of peritoneal tumors in an in vivo xenograft model of EOC. (A) Parental SKOV-3 and SKOV-3 stably
transfected with VCAN shRNA (clone5 and clone6) were used in spheroid formation assay, collected, intraperitoneally injected into abdomens of
athymic nude mice at 3 × 106 cells/mouse (n = 6). Animals were monitored 3 times weekly for 38 days following sacrifice, dissection, and documentation
of visible tumors. Distribution of metastatic lesions formed on omentum, colon, mesentery, stomach, spleen, liver, and peritoneal wall is shown as the
number of animals bearing metastasis at that site. (B) Tumors formed after intraperitoneal injection of either transfected with vector control or parental
SKOV-3, as indicated. Paraffin-embedded tumors were cut in 5 micron sections and stained with haematoxylin&eosin. Images were generated using Aperio
ScanScope; bar, 50 micron. (C) Parental SKOV-3 and SKOV-3 stably transfected with VCAN shRNA (clone5 and clone6) were released from monolayers using
trypsin, suspended in PBS, and intraperitoneally injected into abdomens of athymic nude mice at 3 × 106 cells/mouse (n = 6). A histograms shows volumes
of ascites collected from animals in each experimental and control groups (D). The data were statistically analysed using Student’s t-test; *p< 0.05,
comparisons were made between experimental (VCANsh) and control (SKOV-3) groups.
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http://www.ovarianresearch.com/content/7/1/70show that versican-specific siRNA and shRNA are effective
against formation of EOC peritoneal metastases. These data
provide feasibility of this approach provided that future
technological discoveries will make it possible to use small
RNAs to treat diseases. Another approach that could be
attempted in preclinical models is the use of bio-
neutralizing antibodies against versican. As versican is a se-
creted protein associated with the extracellular matrix, use
of antibodies, if successful, could target many stages of
EOC dissemination starting from peritoneal seeding to the
latest stages characterized by expansion of terminal metas-
tasis. While some of these approaches remain to be tested,
our data presented here emphasize the potential import-
ance of versican in formation and development of periton-
eal metastases of EOC.
Conclusions
Our data elucidate the expression and role of versican in
the formation and development of peritoneal metastases
of EOC from both individual cells and spheroids. Our re-
sults may also suggest that multiple pro-metastatic cellularfunctions, such as adhesion and migration, play a signifi-
cant role in development of metastasis from ovarian
carcinoma.Additional file
Additional file 1: Figure S1. Flow cytometry analysis of versican
expression in parental non-transfected SKOV-3 as well as those transiently
transfected with control (Ctrl) and VCAN siRNAs. (A) Expression of TP53 was
tested in EOC cell lines SKOV-3, OVCA432, and OVCAR3 using Western blot.
Β-Tubulin was a loading control. (B) Intracellular expression of versican in
non-transfected SKOV-3 (Non-transfected), SKOV-3 transfected with control
siRNA (Control siRNA), and SKOV-3 transfected with versican-specific siRNAs
(VCAN siRNA) was probed with flow cytometry as described in Methods. Black
line – cells only, green line – secondary antibody only, red line – isotype
control antibody + secondary antibody, blue line – primary anti-versican
antibody + secondary antibody. Numbers on the graphs represent percentage
of versican-specific species in non-transfected SKOV-3 as well as those
transiently transfected with control and VCAN-specific siRNAs. Representative
of at least three independent experiments. (C) Expression of VCAN isoforms
detected by quantitative PCR in parental SKOV-3 as well as those transiently
and stably transfected with either control siRNAs, or VCAN siRNAs, or
scrambled shRNAs, or VCAN shRNAs (clones 2, 5, and 6), as indicated.
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http://www.ovarianresearch.com/content/7/1/70Additional file 2: Figure S2. Immunofluorescence staining of versican in
parental non-transfected SKOV-3 as well as those transiently transfected with
control (Ctrl) and VCAN siRNAs. (A) Non-transfected SKOV-3 (NT), SKOV-3
transfected with control siRNA (Ctrl si), and SKOV-3 transfected with
versican-specific siRNAs (VCAN si) were cultured to a nearly complete
monolayer and probed for surface versican expression using anti-versican
antibodies (clone 12C5, Iowa Developmental Studies Hybridoma Bank)
and anti-mouse Alexa430 (Molecular Probes) as described in Methods.
Nuclear DNA was visualized using DAPI. Images were taken using Zeiss
AxioObserverD.1 fluorescence microscope using a DAPI and GFP filters
for DAPI and versican, respectively, using a built-in black&white camera
with a 20 × magnification on the objective. Images were pseudo colored
green (for versican) and blue (for DAPI) and superimposed. (B) Intensity
of the versican staining was measured using a line scan feature of
ImageJ (NIH). Seven vertical lines were drawn in random places across
the images, integrated density was determined with the ImageJ
software, averaged and plotted on the histogram. Student’s t-test was
used to analyze differences in versican staining.
Additional file 3: Figure S3. Analysis of extracellular versican levels by
immunofluorescence in SKOV-3 stably transfected with scrambled and VCAN
siRNAs. (A) SKOV-3 stably transfected with scrambled and versican-specific
shRNAs were cultured to a nearly complete monolayer and probed for
surface versican expression using anti-versican antibodies (clone 12C5, Iowa
Developmental Studies Hybridoma Bank) and anti-mouse Alexa555 (Molecular
Probes) as described in Methods. Nuclear DNA was visualized using DAPI.
Images were taken using Zeiss AxioObserverD.1 fluorescence microscope
using a DAPI and GFP filters for DAPI and versican, respectively, using a built-in
black&white camera with a 20 ×magnification on the objective. Images were
pseudo colored red (for versican) and blue (for DAPI) and superimposed. (B)
Intensity of the versican staining was measured using a line scan feature of
ImageJ (NIH). Seven vertical lines were drawn in random places across the
images, integrated density was determined with the ImageJ software,
averaged and plotted on the histogram. Student’s t-test was used to analyze
differences in versican staining.
Additional file 4: Figure S4. Cell proliferation assay. SKOV-3 stably
transfected with vector control, scrambled shRNA, versican shRNA (clones
5 and 6), as indicated, or non-transfected (SKOV-3) were plated at 10%
density in 48WP, allowed to attach, starved overnight, and were
stimulated with complete media for 24 h followed by WST1 assay as
described in Methods. OD430 values were obtained, averaged from at least
three independent experiments, plotted, and data were analysed with
Student’s t-test. *p < 0.05.
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